Switch theme
Sign up to access all valuation multiples
Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of Covid-19 vaccines and Covid-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.
2012
134
LTM Revenue n/a
LTM EBITDA n/a
$376M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medigen Vaccine Biologics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Medigen Vaccine Biologics achieved revenue of $18.3M and an EBITDA of $2.3M.
Medigen Vaccine Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medigen Vaccine Biologics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $11.8M | $18.3M | XXX | XXX | XXX |
| Gross Profit | -$6.4M | $7.0M | XXX | XXX | XXX |
| Gross Margin | -55% | 38% | XXX | XXX | XXX |
| EBITDA | -$29.9M | $2.3M | XXX | XXX | XXX |
| EBITDA Margin | -254% | 12% | XXX | XXX | XXX |
| Net Profit | -$44.5M | -$35.0M | XXX | XXX | XXX |
| Net Margin | -378% | -192% | XXX | XXX | XXX |
| Net Debt | $14.3M | $9.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medigen Vaccine Biologics's stock price is TWD 43 (or $1).
Medigen Vaccine Biologics has current market cap of TWD 14.0B (or $424M), and EV of TWD 12.5B (or $376M).
See Medigen Vaccine Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $376M | $424M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medigen Vaccine Biologics has market cap of $424M and EV of $376M.
Medigen Vaccine Biologics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Medigen Vaccine Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medigen Vaccine Biologics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $376M | XXX | XXX | XXX |
| EV/Revenue | 20.6x | XXX | XXX | XXX |
| EV/EBITDA | 166.4x | XXX | XXX | XXX |
| P/E | -174.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 2158.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedigen Vaccine Biologics's NTM/LTM revenue growth is n/a
Medigen Vaccine Biologics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Medigen Vaccine Biologics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medigen Vaccine Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medigen Vaccine Biologics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 55% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -108% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 90% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medigen Vaccine Biologics acquired XXX companies to date.
Last acquisition by Medigen Vaccine Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Medigen Vaccine Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medigen Vaccine Biologics founded? | Medigen Vaccine Biologics was founded in 2012. |
| Where is Medigen Vaccine Biologics headquartered? | Medigen Vaccine Biologics is headquartered in Taiwan. |
| How many employees does Medigen Vaccine Biologics have? | As of today, Medigen Vaccine Biologics has 134 employees. |
| Is Medigen Vaccine Biologics publicy listed? | Yes, Medigen Vaccine Biologics is a public company listed on ROCO. |
| What is the stock symbol of Medigen Vaccine Biologics? | Medigen Vaccine Biologics trades under 6547 ticker. |
| When did Medigen Vaccine Biologics go public? | Medigen Vaccine Biologics went public in 2015. |
| Who are competitors of Medigen Vaccine Biologics? | Similar companies to Medigen Vaccine Biologics include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Medigen Vaccine Biologics? | Medigen Vaccine Biologics's current market cap is $424M |
| What is the current revenue growth of Medigen Vaccine Biologics? | Medigen Vaccine Biologics revenue growth between 2023 and 2024 was 55%. |
| Is Medigen Vaccine Biologics profitable? | Yes, Medigen Vaccine Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
